{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:16:39Z","timestamp":1788952599304,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1804100"],"award-info":[{"award-number":["2025ZD1804100"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB1060401"],"award-info":[{"award-number":["XDB1060401"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0830000"],"award-info":[{"award-number":["XDB0830000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["21140902000"],"award-info":[{"award-number":["21140902000"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25D9023"],"award-info":[{"award-number":["U25D9023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1404400"],"award-info":[{"award-number":["22XD1404400"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.isci.2026.115062","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:49Z","timestamp":1771434169000},"page":"115062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaco-genomic characterization of pancreatic and biliary tract cancer tumoroids for drug response"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5753-7215","authenticated-orcid":false,"given":"Kun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115062_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101844","article-title":"Role of genetic testing in hepatic, pancreatic, and biliary cancers","volume":"44","author":"Hewitt","year":"2022","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","article-title":"Improving outcomes of patients with pancreatic cancer","volume":"22","author":"Dreyer","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.115062_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-022-10421-w","article-title":"Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers","volume":"23","author":"Haslam","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2026.115062_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.isci.2026.115062_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12943-024-02003-0","article-title":"Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications","volume":"23","author":"Park","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.115062_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2026.115062_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","article-title":"Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures","volume":"22","author":"Feng","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2026.115062_bib10","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.115062_bib11","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","article-title":"Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology","volume":"56","author":"Thorel","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.isci.2026.115062_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.115062_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jare.2024.09.011","article-title":"Developing Patient-Derived 3D-Bioprinting models of pancreatic cancer","volume":"74","author":"Sun","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.isci.2026.115062_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.115062_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115062_bib16","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1582-4934.2012.01541.x","article-title":"AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR","volume":"16","author":"Zhou","year":"2012","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.isci.2026.115062_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112913","volume":"209","author":"Xiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.115062_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12672-024-01110-0","article-title":"Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives","volume":"15","author":"Liu","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.isci.2026.115062_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.115062_bib22","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2026.115062_bib23","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115062_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151688","article-title":"Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors","volume":"760","author":"Kale","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2026.115062_bib25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41467-017-00350-9","article-title":"G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115062_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21873\/cgp.20224","article-title":"Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis","volume":"17","author":"Kato","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.isci.2026.115062_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003483","article-title":"PUMA and BIM are required for oncogene inactivation-induced apoptosis","volume":"6","author":"Bean","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2026.115062_bib28","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41401-018-0205-5","article-title":"Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells","volume":"40","author":"Cao","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2026.115062_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.115062_bib31","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115062_bib32","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.115062_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115062_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.115062_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.115062_bib36","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1038\/s41467-024-54387-8","article-title":"Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115062_bib37","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision Medicine in Biliary Tract Cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib38","article-title":"Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application","volume":"4","author":"Ren","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.115062_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.02.029","article-title":"Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity","volume":"183","author":"Passarelli","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2026.115062_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-023-01359-x","article-title":"Intact regulation of G1\/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kalpha inhibitors","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.115062_bib41","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115062_bib42","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1158\/0008-5472.CAN-23-3574","article-title":"Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer","volume":"84","author":"Becker","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115062_bib43","doi-asserted-by":"crossref","first-page":"13271","DOI":"10.1021\/acs.jmedchem.4c01192","article-title":"Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2026.115062_bib44","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/1078-0432.CCR-12-0738","article-title":"Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response","volume":"18","author":"Wong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115062_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12064-012-0162-3","article-title":"Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples","volume":"131","author":"Wagner","year":"2012","journal-title":"Theor. Biosci."},{"key":"10.1016\/j.isci.2026.115062_bib46","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/thno.23824","article-title":"G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226004372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226004372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:41:07Z","timestamp":1788950467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226004372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2589004226004372"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115062","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaco-genomic characterization of pancreatic and biliary tract cancer tumoroids for drug response","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115062"}}